Evidence map›Paper›PMID 34688290›Full record

ArticleHealth and quality of life outcomes2021

Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis.

Jonathan I Silverberg, Amy DeLozier, Luna Sun, Jacob P Thyssen, Brian Kim, Gil Yosipovitch, Fabio P Nunes, P Cristian Gugiu, Helen A Doll, Lawrence F Eichenfield

3 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Health and quality of life outcomes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03334396 phase3completednot on this map

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

TypeinterventionalSponsorEli Lilly and CompanyRan2017 to 2019Enrolled660ConditionsAtopic DermatitisArmsBaricitinib, Placebo
NCT03334422 phase3completednot on this map

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Patients With Moderate to Severe Atopic Dermatitis

TypeinterventionalSponsorEli Lilly and CompanyRan2017 to 2018Enrolled615ConditionsAtopic DermatitisArmsBaricitinib, Placebo
NCT03435081 phase3completednot on this map

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

TypeinterventionalSponsorEli Lilly and CompanyRan2018 to 2021Enrolled440ConditionsAtopic DermatitisArmsBaricitinib, Placebo
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Jonathan I SilverbergGeorge Washington University, Washington, DC, USA.
Amy DeLozierLilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, 46285, USA. delozier_amy@lilly.com.ORCID http://orcid.org/0000-0001-8543-4534
Luna SunLilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, 46285, USA.
Jacob P ThyssenBispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
Brian KimPied Piper Consulting, LLC, St. Louis, MO, USA.
Gil YosipovitchMiller School of Medicine, University of Miami, Miami, FL, USA.
Fabio P NunesLilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, 46285, USA.
P Cristian GugiuClinical Outcomes Solutions, Chicago, IL, USA.
Helen A DollClinical Outcomes Solutions, Folkestone, Kent, UK.
Lawrence F EichenfieldUniversity of California San Diego, San Diego, CA, USA.
Eli Lilly (United States) · USGeorge Washington University · USHealth Outcomes Solutions (United States) · USUniversity of California San Diego · USUniversity of Copenhagen · DKUniversity of Miami · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Itch Numeric Rating Scale (NRS), Skin Pain NRS, and Atopic Dermatitis Sleep Scale (ADSS) are self-administered patient-reported outcome (PRO) instruments developed to assess symptoms in patients with atopic dermatitis (AD). The objective of this study was to evaluate the psychometric properties (reliability, validity, and responsiveness) and interpretability thresholds of these PROs using data from three pivotal Phase 3 studies in adults.

methodsBREEZE-AD1, BREEZE-AD2, and BREEZE-AD5 evaluated the safety and efficacy of baricitinib in adults with moderate-to-severe AD. Clinician-reported outcomes and other PROs commonly assessed in patients with AD were used to estimate meaningful changes and evaluate test-retest reliability, convergent and divergent validity, known-groups validity, responsiveness, and meaningful change thresholds (MCTs) of the Itch NRS, Skin Pain NRS, and ADSS.

resultsThe test-retest reliability of the Itch NRS, Skin Pain NRS, and ADSS was evidenced by generally large intraclass correlation coefficients (> 0.7) in stable groups of patients between baseline and Week 1 and Weeks 4 and 8. Moderate-to-large correlations (r > 0.4) at baseline and Week 16 were generally observed between each measure and other PROs measuring the same concept, supporting convergent validity. Small-to-moderate correlations with clinician-reported outcomes demonstrated divergent validity. Each instrument was able to distinguish between known groups of disease severity as assessed using other indicators of AD severity. The responsiveness of the Itch NRS, Skin Pain NRS, and ADSS scales was demonstrated through significant differences in their change scores from baseline to Week 16 between categories of change in another PRO also from baseline to Week 16. Thresholds for interpreting meaningful change were estimated as - 4.0 for the 0-10 Itch and Skin Pain NRS items; - 1.25 for the 0-4 ADSS Items 1 and 3 and; - 1.50 for the 0-29 ADSS Item 2, these equivalent to moderate degrees of change.

conclusionsResults of this study demonstrate that the psychometric properties of the Itch NRS, Skin Pain NRS, and ADSS are good to excellent. These findings support the use of these instruments in daily assessment of AD symptoms in adults with moderate-to-severe AD. Trial registration ClinicalTrials.gov numbers: NCT03334396, NCT03334422, and NCT03435081.

Indexed as

Dermatitis, AtopicAdultHumansPainPsychometricsQuality of LifeReproducibility of ResultsSeverity of Illness IndexSleepAtopic dermatitisAtopic dermatitis sleep scaleConvergent-divergent validityItch NRSNumeric rating scalePatient-reported outcomePsychometricReliabilityResponsivenessSkin pain NRSValidity

Identifiers

PMID34688290
PMCPMC8542315
OpenAlexW3208185430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.